ABT-239

ABT-239
Identifiers

IUPAC name 4-(2-{2-[(2R)-2-Methylpyrrolidin-1-yl]ethyl}- benzofuran-5-yl)benzonitrile
CAS Number	460746-46-7
PubChem CID	9818903
IUPHAR/BPS	1218
ChemSpider	7994652^Y
ChEMBL	CHEMBL351231^Y
Chemical and physical data
Formula	C₂₂H₂₂N₂O
Molar mass	330.42 g/mol
3D model (Jmol)	Interactive image
SMILES N#CC1=CC=C(C2=CC3=C(C=C2)OC(CCN4[C@@H](CCC4)C)=C3)C=C1
InChI InChI=1S/C22H22N2O/c1-16-3-2-11-24(16)12-10-21-14-20-13-19(8-9-22(20)25-21)18-6-4-17(15-23)5-7-18/h4-9,13-14,16H,2-3,10-12H2,1H3/t16-/m1/s1^Y Key:KFHYZKCRXNRKRC-MRXNPFEDSA-N^Y

ABT-239 is an H₃-receptor inverse agonist developed by Abbott. It has stimulant and nootropic effects, and has been investigated as a treatment for ADHD, Alzheimer's disease, and schizophrenia. ABT-239 is more active at the human H₃ receptor than comparable agents such as thioperamide, ciproxifan, and cipralisant. It was ultimately dropped from human trials after showing the dangerous cardiac side effect of QT prolongation, but is still widely used in animal research into H₃ antagonists / inverse agonists.